c‐Met‐dependent phosphorylation of RhoA plays a key role in gastric cancer tumorigenesis

Jianjun Liu,Shun Li,Shangxiang Chen,Shuai Chen,Qirong Geng,Dazhi Xu
DOI: https://doi.org/10.1002/path.5287
2019-06-27
The Journal of Pathology
Abstract:RhoA has been identified as having a gain‐of‐function mutation in approximately 20% of diffuse gastric cancer patients. However, the carcinogenic role of RhoA mutations in gastric cancer is unclear. In the present study, we report that RhoA directly interacts with c‐Met and can be phosphorylated by c‐Met at Y42 before subsequent K48‐linked polyubiquitination and proteasome‐mediated protein degradation. Y42C‐mutated RhoA exhibits higher protein levels and promotes the proliferation and motility of gastric cancer cells. Interestingly, a c‐Met inhibitor significantly repressed the growth of gastric cancer cells transfected with wild type RhoA but not RhoA mutated at Y42 <i>in vivo</i> and <i>in vitro</i>. Analyses of human gastric cancer tissues showed that the combined levels of p‐c‐Met and p‐RhoA are a better predictor for prognosis than either factor alone. Taken together, our findings unravel the mechanism by which the RhoA Y42 mutant is linked to poor prognosis in gastric cancer. Moreover, this study helps to identify a strategy for patient stratification and optimization of targeted c‐Met therapy.
oncology,pathology
What problem does this paper attempt to address?